Phase 2 trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck... von Obara, Grzegorz, Sun, Jichao, Loo, Deryk, Bohac, Gerry C.

Volltext

Preliminary dose escalation results from a phase I/II, first-in-human study of MGC018 (anti-B7-H3 antibody-drug conjugate) in patients with advanced solid tumors von Powderly, John D., Jang, Sekwon, Lohr, Joanna, Spira, Alexander I., Bohac, Gerry C., Sharma, Manish

Volltext

Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors von Jang, Sekwon, Powderly, John D., Spira, Alexander I., Bakkacha, Ouiam, Loo, Deryk, Bohac, Gerry C., Sharma, Manish

Volltext

Assessment of treatment with panitumumab, cetuximab, and bevacizumab among mCRC patients with wild-type RAS or BRAF treated at community cancer centers in the United States von Garawin, Tamer, Lowe, Kimberly, Kelsh, Michael Anthony, Bohac, Gerry C.

Volltext

Characterization of KRAS, NRAS, and BRAF testing and timing among mCRC patients treated at community cancer centers in the United States von Lowe, Kimberly, Kelsh, Michael Anthony, McCarl, Kevin, Bohac, Gerry C.

Volltext

Characterization of KRAS, NRAS, and BRAF testing and timing among mCRC patients treated at community cancer centers in the United States von Lowe, Kimberly, Kelsh, Michael Anthony, McCarl, Kevin, Bohac, Gerry C.

Volltext

Assessment of treatment with panitumumab, cetuximab, and bevacizumab among mCRC patients with wild-type RAS or BRAF treated at community cancer centers in the United States von Lowe, Kimberly, Garawin, Tamer, Kelsh, Michael Anthony, Bohac, Gerry C.

Volltext

Clinical outcomes from a retrospective registry of patients with locally advanced/metastatic synovial sarcoma and myxoid round cell liposarcoma von Attia, Steven, Pollack, Seth, Van Tine, Brian Andrew, Chawla, Sant P., Druta, Mihaela, Burgess, Melissa Amber, Bohac, Gerry C., Somaiah, Neeta

Volltext

Comparing cancer patient and provider perspectives on fatigue and pain von Williams, Loretta A., Bohac, Gerry C., Badre, Sejal, Cella, David

Volltext

An assessment of the prevalence and incidence of comorbidities among patients with metastatic colorectal cancer in the United States using SEER-Medicare data von Lowe, Kimberly, Doan, Quan, Gleeson, Michelle L., Kelsh, Michael Anthony, Bohac, Gerry C., Danese, Mark D.

Volltext

A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1 + soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival von Chawla, Sant P., Van Tine, Brian Andrew, Pollack, Seth, Ganjoo, Kristen N., Elias, Anthony D., Riedel, Richard F., Attia, Steven, Choy, Edwin, Okuno, Scott H., Agulnik, Mark, von Mehren, Margaret, Livingston, Michael B., Keedy, Vicki Leigh, Verschraegen, Claire F., Philip, Tony, Bohac, Gerry C., Yurasov, Sergey, Lu, Hailing, Chen, Michael, Maki, Robert G.

Volltext

Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas (STS) von Somaiah, Neeta, Chawla, Sant P., Block, Matthew Stephen, Morris, John Charles, Do, Khanh Tu, Kim, Joseph W., Druta, Mihaela, Sankhala, Kamalesh Kumar, Hwu, Patrick, Gnjatic, Sacha, Lu, Hailing, Kenney, Richard T., Bohac, Gerry C., Pollack, Seth

Volltext

Association of CMB305 or LV305-induced and baseline anti-NY-ESO-1 immunity with survival in recurrent cancer patients von Pollack, Seth, Lu, Hailing, Somaiah, Neeta, Chawla, Sant P., Morris, John Charles, Do, Khanh Tu, Kim, Joseph W., Block, Matthew Stephen, Vignali, Marissa, Rytlewski, Julie, Yusko, Erik, Hsu, Frank J., Bohac, Gerry C., Gnjatic, Sacha, Ter Meulen, Jan

Volltext

Survival effects of erythropoiesis-stimulating agents (ESAs) in patients with breast cancer: A meta-analysis von Leyland-Jones, Brian, Aapro, Matti S., Moebus, Volker, Nitz, Ulrike, O'Shaughnessy, Joyce, Pronzato, Paolo, Untch, Michael, Tomita, Dianne, Bohac, Gerry C.

Volltext

Survival effects of erythropoiesis-stimulating agents (ESAs) in patients with breast cancer: A meta-analysis von Leyland-Jones, Brian, Aapro, Matti S., Moebus, Volker, Nitz, Ulrike, O'Shaughnessy, Joyce, Pronzato, Paolo, Untch, Michael, Tomita, Dianne, Bohac, Gerry C.

Volltext